TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04559867

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle knife fistulotomy
Description: A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphincterotomy
Description: A sphincterotomy uses a heated metal wire to cut the opening to the bile duct after a wire has been passed into it.
Study: NCT01148836

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q-10 in Pulmonary Hypertension subjects
Description: Take 100mg Co-Q for three times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q-10 in Normal Control subjects
Description: Take 100mg Co-Q for three times daily
Study: NCT01124227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icodextrin
Description: 2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: icodextrin
Description: 2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
Study: NCT01256463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Study: NCT00700102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
Study: NCT01667562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Daily oral doses administered until disease progression or unacceptable toxicity or death.
Study: NCT03653468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent training (CT)
Description: The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
Study: NCT00196859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate, Capecitabine
Description: Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
Study: NCT00561067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
Study: NCT04624581

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device
Description: This intervention measures the response to electrical stimulation of the sural nerve using a pair of percutaneous electrodes placed at the external malleolar retro passage of the nerve (2 cm apart) and connected to the stimulation device (Nicolet Vicking). Reflex muscle responses will be collected using surface electrodes placed on the femoral biceps muscle of the participant and connected to an Electromyogram recording device.~The RIII will be determined twice (rest period between each 10-minute). In order to induce the reflex nociceptive flexion response, repeated cutaneous electrical stimulations (30 to 40) will be applied at the level of the sural nerve following a variable interval of 6 to 10 seconds in order to overcome the phenomena of habituation and predictability. Each stimulus test will consist of a single rectangular pulse of 0.5 ms, of variable intensity (0-100mA) until a reflex nociceptive flexion threshold is detected or a maximum current of 100 mA is reached
Study: NCT00917098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Counseling
Description: Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
Study: NCT04624581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device
Description: This intervention measures the response to electrical stimulation of the sural nerve using a pair of percutaneous electrodes placed at the external malleolar retro passage of the nerve (2 cm apart) and connected to the stimulation device (Nicolet Vicking). Reflex muscle responses will be collected using surface electrodes placed on the femoral biceps muscle of the participant and connected to an Electromyogram recording device.~The RIII will be determined twice (rest period between each 10-minute). In order to induce the reflex nociceptive flexion response, repeated cutaneous electrical stimulations (30 to 40) will be applied at the level of the sural nerve following a variable interval of 6 to 10 seconds in order to overcome the phenomena of habituation and predictability. Each stimulus test will consist of a single rectangular pulse of 0.5 ms, of variable intensity (0-100mA) until a reflex nociceptive flexion threshold is detected or a maximum current of 100 mA is reached
Study: NCT04374981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 100mg
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg
Description: Tablets
Study: NCT00647465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaccine
Description: IFNalpha 2b
Study: NCT03598192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP
Description: The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVB
Description: The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
Study: NCT02220660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1744 CL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 54903 XX
Study: NCT03598192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine has been treated the both group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine has been treated the both group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil has been included in Arm/Group Descriptions
Study: NCT00647465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03598192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil has been included in Arm/Group Descriptions
Study: NCT01313767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin type A
Description: Botulinum Toxin type A
Study: NCT00300586

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: observation
Description: observation, second line chemotherapy if progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1250 mg/m² D1, D8 q21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg daily
Study: NCT03657706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: group A (Tunnel procedure with subepithelial connective tissue graft (sCTG)
Description: Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: group B (Tunnel procedure with modified free gingival graft (mFGG))
Description: modified free gingival graft (autogenous graft) will be harvested from the palate and will be used with the prepared tunnel to be used in treating gingival recession
Study: NCT02366845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma
Description: An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre-Transfusion International Normalized Ratio (INR)
Description: INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Transfusion International Normalized Ratio (INR)
Description: INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post-Transfusion International Normalized Ratio (INR)
Description: INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Post-Transfusion International Normalized Ratio (INR)
Description: INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.
Study: NCT01453634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunacalcipol 180
Description: 4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunicalcipol 270
Description: 8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
Study: NCT03573895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam-Roller
Description: Application of foam roller in the posterior part of thigh.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular stretching
Description: Use of a neuromuscular stretching applied to the hamstring muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasive stretching
Description: Use of a pasive stretching applied to the hamstring muscles
Study: NCT04486781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + sEphB4-HSA
Description: sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
Study: NCT05458089

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FDG
Description: 18F-FDG intravenous injection

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FDG
Description: 18F-FDG intravenous injection
Study: NCT03270267

Intervention type: OTHER
Intervention: Questionnaires
Study: NCT02689076

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIE Notification
Description: VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIE Notification
Description: VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care transitions intervention
Description: Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
Study: NCT00434759

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive therapy
Description: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
Study: NCT02234453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minicare H-2000
Description: Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
Study: NCT02985229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: The option of home or clinic administration of 200 mg oral mifepristone
Study: NCT03162614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E
Description: Subjects will receive intramuscular injection of RTS,S/AS01E.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E
Description: Subjects will receive intramuscular injection of RTS,S/AS01E.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B
Description: Subjects will receive intramuscular injection of RTS,S/AS01B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01B
Description: Subjects will receive intramuscular injection of RTS,S/AS01B.
Study: NCT00434759

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stepped care program based on cognitive therapy
Description: starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
Study: NCT04225091

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testing product
Description: consume 1 bottle (50 mL) per day for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blank
Description: consume 1 bottle (50 mL) per day for 28 days
Study: NCT02985229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
Study: NCT04299308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload
Study: NCT02244489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Description: Momelotinib (MMB) tablet(s) administered orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Description: Momelotinib (MMB) tablet(s) administered orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
Study: NCT03219294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium 0.1 mg/kg
Description: Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium 0.2mg/kg
Description: Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
Study: NCT01141439

Intervention type: DRUG
Intervention: Extra-fine hydrofluoroalkane-beclomethasone dipropionate
Description: Initiation of HFA-BDP (any dose) in steroid naive patients via MDI

Intervention type: DRUG
Intervention: Extra-fine hydrofluoroalkane-beclomethasone dipropionate
Description: An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI

Intervention type: DRUG
Intervention: Fluticasone propionate
Description: An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI

Intervention type: DRUG
Intervention: Beclomethasone dipropionate
Description: An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
Study: NCT03162614

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B
Description: Subjects will receive intramuscular injection of RTS,S/AS01B.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sporozoite-infected mosquitoes challenge.
Description: Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs.
Study: NCT02958202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 044 IV 6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 044 IV 9 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 044 SC 6 mg/kg
Study: NCT02148432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine infusion rate, 0.5 mcg/kg/hr
Description: continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine infusion rate, 1.0 mcg/kg/hr
Description: continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
Study: NCT00404170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-CIT and SPECT imaging
Description: Optional ongoing B-CIT SPECT imaging scans at follow-up visits
Study: NCT00875056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle